Supernus Pharmaceuticals, Inc. (SUPN)
52.12
+0.67
(+1.30%)
USD |
NASDAQ |
May 07, 11:57
Supernus Pharmaceuticals Cash from Investing (Quarterly) : -19.22M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -209.50M |
| Corcept Therapeutics, Inc. | 4.542M |
| BridgeBio Pharma, Inc. | -13.75M |
| Cytokinetics, Inc. | 145.49M |
| Oncotelic Therapeutics, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 66.52M |
| Cash from Financing (Quarterly) | 9.115M |
| Free Cash Flow | 82.24M |
| Free Cash Flow Per Share (Quarterly) | 1.154 |
| Free Cash Flow to Equity (Quarterly) | 66.60M |
| Free Cash Flow to Firm (Quarterly) | 66.52M |
| Free Cash Flow Yield | 2.77% |